N
Company Profile
NanoTess
Develops technology to treat chronic wounds with a topical gel containing micron-scale catalysts.
Canadian company (AB)1
Dispatches
Apr 15, 2026
Latest story
Editorial lens
Why Boreal Signal tracks this company
We track NanoTess to understand how its decisions in catalytic gel/biotechnology affect the market and its Canadian operations.
Profile facts
- Coverage focus
- Catalytic gel/biotechnology
- Related stories
- 1
- Last reviewed
- May 25, 2026
Profiles are based on Boreal Signal reporting and are updated as new stories are published.
All stories about this company
Catalytic Breakthrough: How NanoTess is Redefining Chronic Wound Care in Canadian Healthcare
Catalytic Gel/biotechnologyApr 15, 20262 min
Catalytic Breakthrough: How NanoTess is Redefining Chronic Wound Care in Canadian Healthcare
From the outset, NanoTess, under the visionary leadership of Megan Leslie, has focused not merely on treating symptoms, but on addressing the fundamental biochemistry of stalled healing. The conceptual genius...
Read article